The superior tumor-to-kidney absorbed dose ratio for [177Lu]Lu-HTK03170 compared to that of [177Lu]Lu-PSMA-617 is mainly due to the use of the more PSMA-selective Lys-urea-Aad pharmacophore compared with the common Lys-urea-Glu pharmacophore in [177Lu]Lu-PSMA-617. The gene discussed is FOLH1; the disease is neoplasm.